Autolus Therapeutics plc
AUTL
$1.60
$0.021.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.60% | 1.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.60% | 1.30% | |||
| Cost of Revenue | -3.97% | 117.67% | |||
| Gross Profit | 15.12% | -599.82% | |||
| SG&A Expenses | 16.10% | 19.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.87% | 13.00% | |||
| Operating Income | -0.70% | -17.00% | |||
| Income Before Tax | -16.45% | -65.37% | |||
| Income Tax Expenses | -322.37% | 34.01% | |||
| Earnings from Continuing Operations | -14.17% | -65.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.17% | -65.11% | |||
| EBIT | -0.70% | -17.00% | |||
| EBITDA | -0.59% | -17.39% | |||
| EPS Basic | -14.16% | -65.17% | |||
| Normalized Basic EPS | -16.04% | -65.32% | |||
| EPS Diluted | -14.16% | -65.17% | |||
| Normalized Diluted EPS | -16.04% | -65.32% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||